Original Article
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis: Subgroup analysis of Latin American patients in the phase 3 randomized UNCOVER-3 study
Comparación de ixekizumab y etanercept o placebo en la psoriasis de moderada a grave: análisis del subgrupo de pacientes latinoamericanos de la fase 3 del estudio aleatorizado UNCOVER-3
F. Valenzuelaa, C. de la Cruz Fernandezb, R.L. Galimbertic, S. Gürbüzd, M. McKean-Matthewse, L. Goncalvesf,
, R. Romitig
Corresponding author
a Departamento de Dermatología, Facultad de Medicina Universidad de Chile, Probity Medical Research, Santiago, Chile
b Clinica Dermacross, Santiago, Chile
c Universidad de Buenos Aires Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
d Eli Lilly and Company, Indianapolis, USA
e inVentiv Health, USA
f Eli Lilly and Company, São Paulo, Brazil
g Department of Dermatology, Hospital das Clínicas de Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Read
6346
Timeswas read the article
2360
Total PDF
3986
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 6 | 16 | 4 | 20 |
| 2025 5 | 140 | 38 | 178 |
| 2025 4 | 123 | 25 | 148 |
| 2025 3 | 135 | 16 | 151 |
| 2025 2 | 171 | 39 | 210 |
| 2025 1 | 86 | 38 | 124 |
| 2024 12 | 85 | 39 | 124 |
| 2024 11 | 110 | 57 | 167 |
| 2024 10 | 73 | 48 | 121 |
| 2024 9 | 65 | 22 | 87 |
| 2024 8 | 94 | 46 | 140 |
| 2024 7 | 85 | 36 | 121 |
| 2024 6 | 68 | 33 | 101 |
| 2024 5 | 71 | 32 | 103 |
| 2024 4 | 75 | 26 | 101 |
| 2024 3 | 69 | 27 | 96 |
| 2024 2 | 58 | 28 | 86 |
| 2024 1 | 55 | 32 | 87 |
| 2023 12 | 50 | 15 | 65 |
| 2023 11 | 60 | 29 | 89 |
| 2023 10 | 56 | 17 | 73 |
| 2023 9 | 59 | 35 | 94 |
| 2023 8 | 38 | 10 | 48 |
| 2023 7 | 57 | 37 | 94 |
| 2023 6 | 45 | 21 | 66 |
| 2023 5 | 41 | 34 | 75 |
| 2023 4 | 41 | 21 | 62 |
| 2023 3 | 72 | 30 | 102 |
| 2023 2 | 65 | 20 | 85 |
| 2023 1 | 42 | 34 | 76 |
| 2022 12 | 90 | 43 | 133 |
| 2022 11 | 49 | 28 | 77 |
| 2022 10 | 30 | 14 | 44 |
| 2022 9 | 23 | 28 | 51 |
| 2022 8 | 23 | 44 | 67 |
| 2022 7 | 34 | 35 | 69 |
| 2022 6 | 39 | 20 | 59 |
| 2022 5 | 39 | 34 | 73 |
| 2022 4 | 38 | 55 | 93 |
| 2022 3 | 52 | 51 | 103 |
| 2022 2 | 28 | 35 | 63 |
| 2022 1 | 31 | 59 | 90 |
| 2021 12 | 33 | 41 | 74 |
| 2021 11 | 33 | 52 | 85 |
| 2021 10 | 37 | 58 | 95 |
| 2021 9 | 39 | 51 | 90 |
| 2021 8 | 40 | 42 | 82 |
| 2021 7 | 43 | 38 | 81 |
| 2021 6 | 40 | 30 | 70 |
| 2021 5 | 47 | 62 | 109 |
| 2021 4 | 82 | 68 | 150 |
| 2021 3 | 72 | 54 | 126 |
| 2021 2 | 59 | 51 | 110 |
| 2021 1 | 41 | 45 | 86 |
| 2020 12 | 48 | 26 | 74 |
| 2020 11 | 45 | 43 | 88 |
| 2020 10 | 35 | 21 | 56 |
| 2020 9 | 38 | 28 | 66 |
| 2020 8 | 28 | 26 | 54 |
| 2020 7 | 44 | 29 | 73 |
| 2020 6 | 29 | 39 | 68 |
| 2020 5 | 16 | 14 | 30 |
| 2020 4 | 21 | 24 | 45 |
| 2020 3 | 23 | 19 | 42 |
| 2020 2 | 3 | 0 | 3 |
| 2020 1 | 3 | 0 | 3 |
| 2019 12 | 8 | 0 | 8 |
| 2019 11 | 2 | 0 | 2 |
| 2019 9 | 10 | 0 | 10 |
| 2019 8 | 4 | 0 | 4 |
| 2019 7 | 4 | 0 | 4 |
| 2019 6 | 6 | 0 | 6 |
| 2019 5 | 9 | 0 | 9 |
| 2019 4 | 17 | 0 | 17 |
| 2019 3 | 3 | 0 | 3 |
| 2019 2 | 2 | 0 | 2 |
| 2019 1 | 5 | 0 | 5 |
| 2018 12 | 18 | 0 | 18 |
| 2018 11 | 10 | 0 | 10 |
| 2018 10 | 21 | 0 | 21 |
| 2018 9 | 2 | 0 | 2 |
| 2018 5 | 1 | 0 | 1 |
| 2018 2 | 26 | 5 | 31 |
| 2018 1 | 26 | 7 | 33 |
| 2017 12 | 36 | 14 | 50 |
| 2017 11 | 40 | 12 | 52 |
| 2017 10 | 28 | 15 | 43 |
| 2017 9 | 30 | 29 | 59 |
| 2017 8 | 40 | 43 | 83 |
| 2017 7 | 46 | 37 | 83 |
| 2017 6 | 12 | 2 | 14 |
Show all
